The Ontario Institute for Cancer Research (OICR) ranks among the world’s top cancer research institutions and leads multiple national and international cancer research consortia including the International Cancer Genome Consortium, the Canadian Partnership for Tomorrow Program (a 300,000 participant precision health cohort), and the Global Alliance for Genomics and Health. OICR combines a vibrant genomics program with world-class informatics, imaging, diagnostic development, drug development and clinical trials groups in an environment that prioritizes collaboration, cross-disciplinary research, and research/clinical partnerships. OICR emphasizes clinical translation and addresses significant challenges in cancer research with multi-disciplinary and multi-institutional teams.
OICR is seeking a Director of Cancer Genomics to join us to enhance and extend our innovative research program in cancer genomics and technology. The Director will act as a leader within OICR’s Adaptive Oncology program, which blends ‘omics technologies with imaging, pathology and informatics in order to detect cancers at an early stage of their life cycle, to characterize tumour-host interactions, and understand how tumours adapt to therapy over time. This knowledge is used to develop innovative strategies for cancer management.
Research areas of particular interest include:
- Tumor/host interactions, including immunogenomics
- Tumor tissue architecture, including single-cell analysis
- Tumor heterogeneity, evolution and selection
- Development of novel technologies, such as long read sequencing and liquid biopsies
- Use of multiple ‘omics technologies to profile clinical specimens
Qualifications:
- PhD and/or MD at the mid-career to senior level with a proven track record in cancer genomics, next generation sequencing and technology development;
- A relevant international reputation and strong publication record;
- Proven leadership, management experience and communications skills;
- Previous experience in leading multidisciplinary, multi-institutional teams;
- Excellent and broad understanding of the field of genomics, epigenomics and informatics in oncology;
- Eligible to hold the rank of associate or full professor at an Ontario university.
Conditions of Employment
The position will be based at OICR’s core laboratories in the MaRS Centre in Toronto, adjacent to Princess Margaret Cancer Centre, Toronto General Hospital, Mt. Sinai Hospital, SickKids, the University of Toronto’s St. George Campus, and multiple other area research and health care institutions and biotech companies. The Genomics Program comprises 30 full-time staff combining lab technicians, bioinformaticians and computational biologists in Genome Sequence Informatics, and advanced instrumentation including the Illumina Novaseq for short-read sequencing, the Oxford Nanopore PromethION and PacBio for long-read sequencing, and the 10X Genomics Chromium for single-cell sequence analysis. The Director will have access to extensive retrospective and prospective collections of clinical and research materials and to world-class colleagues and collaborators in the fields of informatics, genomics, imaging, pathology, machine learning, and therapeutic development. An academic appointment may be obtained at the University of Toronto. The initial appointment is for five years, renewable pending satisfactory review. A competitive salary and benefits package will be negotiated.
Launched in December 2005, OICR is an independent cancer research institute funded by the Government of Ontario through the Ministry of Research, Innovation and Science.
For more information about OICR, please visit the website at www.oicr.on.ca. To apply for this position, please upload a CV, research statement, and list of references to https://goo.gl/FU9YLJ.
OICR is an inclusive employer dedicated to building a diverse workforce. We encourage applications from all qualified candidates and will accommodate applicants’ needs throughout all stages of the recruitment and selection process. Please advise the Recruiter to ensure your accessibility needs are accommodated throughout this process. Information received relating to accommodation will be addressed confidentially.
